ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.

[Guest guest]

ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.

http://www.earthtimes.org/articles/show/news_press_release,154224.shtml

SCOTTSDALE, Ariz., Aug. 7 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a

wholly owned subsidiary of IR BioSciences Holdings, Inc. (BULLETIN BOARD: IRBO)

, today announced it has finalized a Material Transfer Agreement (MTA) with

VaxGen Inc. (Pink Sheets: VXGN.PK). As part of the agreement, ImmuneRegen will

receive the pharmaceutically active ingredient of VaxGen's anthrax vaccine

candidate, recombinant Protective Antigen, or rPA, to be tested at one of

ImmuneRegen's partnering labs. Commercial terms of the MTA were not disclosed.

VaxGen's rPA102 anthrax vaccine is composed of a purified rPA and an aluminum

salt adjuvant routinely used in many vaccines. ImmuneRegen will be testing for

adjuvant activity of ImmuneRegen's Viprovex® in combination with VaxGen's rPA.

" We are hoping to find that our compound, Viprovex, will demonstrate adjuvant

activity in a rabbit model with the VaxGen vaccine, " said Hal Siegel, Ph.D.,

Senior Director of Product Development and Regulatory Affairs, ImmuneRegen

BioSciences, Inc. " From work we and others have already performed, we hope the

adjuvant activity we recently reported in our studies with influenza vaccines in

mice will be mirrored in testing of Viprovex with VaxGen's rPA antigen. "

Initial studies in a well-established mouse model system have revealed that

Viprovex can both prophylactically and therapeutically have positive effects in

mice exposed to lethal doses of anthrax. Tests results indicated that animals

exposed to lethal doses of anthrax spores were treated with different doses of

Viprovex either before or after anthrax exposure and survival ranged from 20% to

70%.

The MTA with ImmuneRegen BioSciences is separate from VaxGen's effort to

partner its recombinant anthrax vaccine program with another company for the

purpose of carrying on the development and commercialization of the rPA102

product candidate. The company recently completed several milestones including

the development of multiple vaccine formulations showing greatly improved

stability, the completion of bulk drug manufacturing process validation and the

production of clinical-grade bulk drug inventory.

" We are eager to work with such an exceptional vaccine candidate, " says

ImmuneRegen CEO and Founder Wilhelm. " With the previous success that

the rPA vaccine has seen in the lab against anthrax we are convinced that there

is no better candidate to test with our potential adjuvant. "

About Viprovex®

Viprovex® is the trade name used in referring to formulations of

Homspera for potential indications for treatment of viral and bacterial

infections. Homspera is a generic name used by the Company to describe the

synthetic peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is

an analog of the naturally occurring human neuropeptide Substance P, which can

be found throughout the body, including in the airways of humans and many other

species. All of the Company's research and development efforts are early,

pre-clinical stage and Homspera, as Viprovex® has only undergone exploratory

studies to evaluate its biological activity in small animals.

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings, Inc., through its wholly owned subsidiary ImmuneRegen

BioSciences, Inc., is a development stage biotechnology company focused on the

research and development of Homspera and its derivatives Radilex and

Viprovex®, which are designed to be used as countermeasures for multiple

homeland security bioterrorism threats. Homspera is derived from Substance P, a

naturally occurring peptide immunomodulator and homeostatic compound with the

dual effect of improving pulmonary function and the stimulation of the human

immune system. For more information, please visit the company's website at

http://www.immuneregen.com/.

Statements about the Company's future expectations, including statements about

the potential for the Company's drug candidates, science and technology, and all

other statements in this press release other than historical facts, are

" forward-looking statements " within the meaning of Section 27A of the Securities

Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that

term is defined in the Private Securities Litigation Reform Act of 1995. The

Company intends that such forward-looking statements be subject to the safe

harbors created thereby. These future events may not occur as and when expected,

if at all, and, together with the Company's business, are subject to various

risks and uncertainties. The Company's actual results could differ materially

from expected results as a result of a number of factors, including the fact

that preliminary results involved only a small number of test mice, the

subsequent investigations were limited in scope, the

uncertainties inherent in research and development collaborations, pre-

clinical and clinical trials and product development programs, (including, but

not limited to the fact that future results or research and development efforts

may prove less encouraging than current results or cause side effects not

observed in current pre-clinical trials) the evaluation of potential

opportunities, the level of corporate expenditures and monies available for

further studies, capital market conditions, and others set forth in the

Company's periodic report on Form 10-QSB for the three months ended March 31,

2007 and on Form 10-KSB for the twelve months ended December 31, 2006 as filed

with the Securities and Exchange Commission. There are no guarantees that any of

the Company's proposed products will prove to be commercially successful. The

Company undertakes no duty to update forward-looking statements.

Available Topic Expert(s): For information on the listed expert(s), click

appropriate link. K. Wilhelm

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=62606

ImmuneRegen BioSciences